A collection of algorithms for detecting pulmonary arterial hypertension in administrative data has been developed to enhance the integrity and value of research findings and improve quality of care.
Patients with pulmonary arterial hypertension (PAH) who were treated with treprostinil using an implantable infusion pump experienced few serious complications.
Low-risk status is unattainable for most patients with pulmonary arterial hypertension, and the first year from diagnosis is important in defining the longitudinal risk status.
Diagnosing pulmonary hypertension due to left-heart disease requires a systematic approach using clinical history and noninvasive investigations.
Physicians frequently underestimate or overestimate disease progression risk in patients with World Health Organization functional class II pulmonary arterial hypertension.
The purpose of this study was to determine whether baseline pulmonary hypertension influences the outcome of transcatheter mitral valve repair (TMVr) in patients presenting with HF with SMR.
Transthoracic echocardiography may overestimate pulmonary arterial pressure in multiple patient populations and cannot replace right heart catheterization as a confirmatory tool.
The understanding of the role of specific molecular mechanisms causing pulmonary hypertension in people with pulmonary fibrosis is growing but still in its infancy.
Researchers sought to determine if selexipag can be associated with lower hospitalization rates through analysis of real-world hospitalization rates of patients taking either selexipag or treprostinil.
A combinatorial model was devised to predict pulmonary hypertension using systolic pulmonary artery pressure and forced vital capacity in older adults.
